<DOC>
	<DOCNO>NCT01180335</DOCNO>
	<brief_summary>This randomized trial compare standard neoadjuvant chemotherapy genomic driven chemotherapy patient breast cancer .</brief_summary>
	<brief_title>Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy Patients With Breast Cancer</brief_title>
	<detailed_description>After core biopsy , tumor profile use Affymetrix U133plus2 gene expression array . DLD30 score ( Hess , JCO , 2006 ) TOP2A expression quantify . Patients either treat 4FEC follow 4 docetaxel ( standard arm ) genomic-driven regimen ( experiemental arm ) . In experimental arm , patient high DLD30 receive 3 month weekly paclitaxel follow 4 FEC , patient high TOP2A receive 4FEC 4 docetaxel , patient low DLD30 low TOP2A treat 6 cycle docetaxel-capecitabine .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Invasive breast cancer eligible conservative surgery Her2 negative Amount tumor cell &gt; 30 % HES slide RIN &gt; 6 amount RNA &gt; 1 ug No metastasis Subject , age &gt; 18 year &lt; 65 year old Signed write informed consent PS 01 No previous treatment breast cancer Adequate organ function FEVG &gt; 50 % In situ carcinoma Multifocal cancer Her2+ Presence metastasis Genomic test feasible tumor cell &lt; 30 % , RIN &lt; 6 , insufficient amount RNA Organ dysfunction contraindicates chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Genomic driven chemotherapy</keyword>
</DOC>